SUBSCRIBE: Print / Digital / eNewsletter
Dermatologists often combine multiple topical agents on their own, and have been doing so for many years. However, extemporaneous compounding of psoriasis topical agents may not necessarily yield what dermatologists anticipate.
For focal areas of plaque psoriasis, the 650 ms Nd:YAG laser provides equivalent efficacy to the more widely used excimer laser, says an expert who spoke at the South Beach Symposium.
Thanks to the phase 3 study that led to dupilumab's approval in adolescent atopic dermatitis (AD), patients can now avoid off-label treatments that may pose a risk of significant long-term toxicity.
Although the fractional ablative CO2 laser is a first-line treatment for acne scarring, the potential for side effects from repetitive treatments leaves room for improvement with additive therapies, according to a recent review.
![intense pulse light treatment for acne](https://www.dermatologytimes.com/sites/default/files/styles/trc_article_348x228/public/Intense%20pulse%20light%20treatment%20for%20acne%20%28%C2%A9AdobeStock_83008210%29_0.jpeg?itok=wApl71kh "<p>"While the review is a good collection and summarization of a lot of studies,” says Emmy Graber, M.D., MBA, who was not involved with the study, “there’s a paucity of large-scale, randomized, controlled studies looking at the pulsed dye laser for nonvascular indications." <small>(Andrey Popov - stock.adobe.com)</small></p>")
The 595 nm pulsed dye laser (PDL) may provide an effective option for nonvascular conditions, such as scars, acne and molluscum contagiosum, according to a recent review.
Maximizing results and safety of aggressive resurfacing procedures requires painstaking postprocedural care, says Dallas-based plastic and reconstructive surgeon A. Jay Burns, M.D.
![](https://www.dermatologytimes.com/sites/default/files/styles/trc_article_348x228/public/Atopic%20dermatitis%20eczema%20adult%20%28%C2%A9ChairoijShutterstock.com%29_3.jpg?itok=gOzXA9u4 "<p>"Eczematous eruptions have been reported previously in patients on anti-IL-17 antibodies. But the frequency reported here ... is higher than I would expect, considering that I treat many patients with anti-IL-17 antibodies and never see this," says Dr. Lebwohl. <small>(©Chairoij/Shutterstock.com)</small></p>")
A recent chart review found that eczematous eruptions occurred in 5.8% of patients using interleukin (IL)-17 inhibitors for psoriasis. Its authors believe that additional research could help identify which patients may be most at risk.
A phase 2 study shows that the oral Janus kinase (JAK) 1 inhibitor abrocitinib quickly improved atopic dermatitis (AD) severity and symptoms versus placebo with some measures achieving statistically significant separation in days.
New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium.
With extended remissions, high safety and favorable dosing schedules, interleukin (IL)-23 inhibitors are well-suited for a variety of patients with psoriasis, says an expert who spoke at the South Beach Symposium
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
